MedTrace Logo

Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

NCT01673711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2019-10-09

No results posted yet for this study

Summary

This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.

Conditions

  • Lung Cancer
  • Squamous Lung Dysplasia
  • Tobacco Use Disorder

Interventions

DRUG

deuterated phenanthrene tetraol

Given PO

DRUG

pharmacological study

Correlative studies

DRUG

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Stephen S Hecht, PhD · University of Minnesota

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2019-03-31
Completion
2019-09-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673711 on ClinicalTrials.gov